Humabs BioMed, a Subsidiary of Vir Biotechnology Inc., is a leading Swiss antibody therapeutics company that discovers and develops superior monoclonal antibodies directly derived from individuals whose immune system has successfully responded to major diseases. The company currently focuses on infectious diseases, but also has selected antibodies against inflammatory diseases and cancer in the pipeline.